Roche Holding AG's acquisition of Poseida for $1.5bn is a smart move by Big Pharma as allogeneic cell therapies are becoming increasingly de-risked. Despite recent challenges, Roche's diverse ...

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

Alpha-lactalbumin, a multifunctional milk protein, has emerged as a key player in the field of tumour biology. In its native state, the protein is primarily involved in lactose synthesis; however, ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma, with a 97% response rate and low neurotoxicity, potentially differentiating it in a crowded market. Financially robust, ...

Recently, Quinn Peterson and colleagues from Mayo Clinic, USA, discovered a method for making human alpha cells from cultures of immature stem cells. This work was recently published in Stem Cell ...

Alpha-enolase (ENO1) is a multifunctional enzyme primarily known for its role in glycolysis, where it catalyses the conversion of 2-phosphoglycerate to phosphoenolpyruvate. However, ENO1’s ...

Alpha Teknova, Inc. and Pluristyx, Inc. have announced a collaboration to produce and commercialize Pluristyx's PluriFreeze™ product line, which is a cryopreservative and cell wash media system for ...

If stem cell therapies are to reach patients with diabetes, Alzheimer's, sickle cell and other diseases, the infrastructure for delivering those must be planned and not left to wander, said the ...

Mor than 800 million people worldwide are living with diabetes, according to World Health Organization (WHO) estimates, with numbers steadily increasing. Diabetic patients experience abnormally high ...

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...

Discover the challenges of acute myeloid leukaemia linked to inflammatory cell death and the quest for effective therapies.

An update from Alpha Tau Medical Ltd ( ($DRTS) ) is now available. On January 5, 2026, Alpha Tau Medical announced it has submitted the first ...